Cancer chemotherapy: targeting folic acid synthesis by Hagner, Nicole & Joerger, Markus
© 2010 Hagner and Joerger, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Cancer Management and Research 2010:2 293–301
Cancer Management and Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
293
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CMR.S10043
Cancer chemotherapy: targeting folic  
acid synthesis
Nicole Hagner
Markus Joerger
Department of Medical Oncology, 
Cantonal Hospital, St Gallen, 
Switzerland
Correspondence: Markus Joerger
Department of Oncology and 
Hematology, Cantonal Hospital, 
Rorschacherstr. 95, 9007 St Gallen, 
Switzerland
Tel +41 71 4941111
Fax +41 71 4942563
email markus.joerger@kssg.ch
Abstract: Antifolates are structural analogs of folates, essential one-carbon donors in the 
synthesis of DNA in mammalian cells. Antifolates are inhibitors of key enzymes in folate 
metabolism, namely dihydrofolate reductase, β-glycinamide ribonucleotide transformylase, 
5′-amino-4′-imidazolecarboxamide ribonucleotide transformylase, and thymidylate synthetase. 
Methotrexate is one of the earliest anticancer drugs and is extensively used in lymphoma, acute 
lymphoblastic leukemia, and osteosarcoma, among others. Pemetrexed has been approved in 
combination with cisplatin as first-line treatment for advanced non-squamous-cell lung cancer, as 
a single agent for relapsed non-small-cell lung cancer after platinum-containing chemotherapy, 
and in combination with cisplatin for the treatment of pleural mesothelioma. Raltitrexed is 
approved in many countries (except in the United States) for advanced colorectal cancer, but its 
utilization is mainly limited to patients intolerant to 5-fluorouracil. Pralatrexate has recently been 
approved in the United States for relapsed or refractory peripheral T-cell lymphoma. This article 
gives an overview of the cellular mechanism, pharmacology, and clinical use of classical and 
newer antifolates and discusses some of the main resistance mechanisms to antifolate drugs.
Keywords: antifolates, cancer, molecular pharmacology, pemetrexed, methotrexate, folate 
metabolism
Introduction
Folates are essential, one-carbon donors in the synthesis of purines, pyrimidines, serine, 
and methionine, all critical to de novo synthesis of DNA in mammalian cells, as they 
lack the capacity to synthesize folates and require these anionic hydrophilic molecules 
to be transported into the cells via sophisticated transport systems (reduced folate 
carrier, RFC). After folate was discovered to be vital to many cellular processes, the 
antifolates aminopterin and methotrexate (MTX) were synthesized in the early 1940s.1 
In 1948, aminopterin was the first drug to induce temporary remissions in childhood 
leukemia.1,2 Only 10 years later, MTX was part of a therapy regimen that was first 
shown to cure some selected solid tumors, namely choriocarcinoma.3 MTX is still used 
in the treatment of a variety of tumors, including acute lymphocytic leukemia,4 breast 
cancer,5 osteosarcoma,6 primary central nervous system lymphoma,7 and head and neck 
cancer.8 Above all, it is also used in certain autoimmune diseases, such as rheumatoid 
arthritis or psoriasis. Recently, the newer antifolate pemetrexed or   multitargeted anti-
folate (MTA) has been established in the first-line treatment of   mesothelioma9 and 
non-squamous, non-small-cell lung cancer (NSCLC).10 An important task for the future 
is treatment individualization, eg, by identifying genetic   variations in drug pathway-
associated genes with an important impact on clinical outcome in patients receiving Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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antifolates11–13 or the use of therapeutic drug monitoring 
(TDM), eg, with MTX, enabling adequate drug exposure in 
all patients.14,15
Cellular folate metabolism
Folates (pteroylglutamates) belong to the family of B9 
vitamins that are essential to mammalian cells. They form 
a family of cofactors based on the structure of folic acid 
(2-NH2-4-OH-pteroylglutamic acid). Folic acid undergoes 
intracellular reduction first to dihydrofolate and then to 
tetrahydrofolate (THF). Both reduction steps are mediated 
by dihydrofolate reductase (DHFR). The major dietary 
form of folates is 5′-methyl-THF (5′-MTHF). Together with 
homocysteine, MTHF is converted to methionine and THF, 
a vitamin-B12-dependent step that is mediated by methionine 
synthase. THF is the main substrate for folylpolyglutamate 
synthetase (FPGS), which progressively adds glutamates at 
the γ-carboxyl residues. The resulting folate polyglutamates 
are polyanionic molecules that can no longer be trans-
ported through the lipophilic cell membrane. These folate 
  polyglutamates are the biologically active form of folates, 
as they serve as one-carbon donors in de novo synthesis of 
purines, thymidylate, and polyamines. Furthermore, folates 
are required for the synthesis of S-adenosyl methionine, 
which promotes methylation of DNA, histones, lipids, and 
neurotransmitters.16
Antifolate drug metabolism
As structural analogs of folates, antifolates use the same 
transport systems to enter the cells, namely the reduced folate 
receptor (RFC), folate receptors (FR), and the recently dis-
covered proton-coupled folate transporter (PCFT) or soluble 
carrier 46A1 (SLC46A1).16 The RFC plays a dominant role in 
cellular uptake of antifolates, as it has low affinity to its main 
endogenous ligand MTHF. Its affinity to antifolates varies 
from low for MTX to high for talotrexin (PT-523).17 The RFC 
works as an anion exchanger that utilizes the gradient built 
up by an asymmetrical distribution of organic phosphates 
across cell membranes.18,19 The RFC is expressed both in 
tumor cells and normal tissue,20 limiting the tolerability of 
antifolates. On the contrary, the folate receptors FR-α and 
FR-β are overexpressed at the surface of some tumor cells, 
making these tumors vulnerable to antifolate drugs,21,22 The 
FR family consists of two cell-surface receptors (FR-α and 
FR-β) and a constitutively secreted isoform (FR-γ).23,24 FR-α 
is expressed in a number of normal epithelial cells as well 
as in a number of carcinomas, with the exception of car-
cinomas of the head and neck.21 FR-β serves as a myeloid 
differentiation marker and is overexpressed in a variety of 
nonepithelial malignancies,21,25 whereas the expression of 
FR-γ is restricted to hematopoietic tissues.24,26 In contrast to 
the high-capacity and low-affinity RFC, transport by FR-α 
and FR-β is by low-capacity and high-affinity endocytosis.27 
After antifolate transport to the endosomal compartment, 
transport to the intracellular compartment involves the 
PCFT.28,29 Accordingly, mutations in the gene encoding 
for PCFT have been shown to cause rare hereditary folate 
malabsorption.29 In addition to its role in folate endocytosis, 
PCFT also serves as a high-affinity folate-proton symporter 
that is important for the intestinal absorption in the proximal 
small intestine.30 Besides these specific folate transporters, a 
number of other transport systems have been described to be 
involved in the efflux of antifolates, including the multidrug 
resistance-associated proteins MRP1–5 and the breast cancer 
resistance protein (BCRP or ABCG2).31,32
Intracellularly, the classical antifolates undergo poly-
glutamation by FPGS, resulting in effective intracellular 
retention and increased affinity of the antifolates to their 
target enzymes.33–36 The nonclassical lipophilic antifolates 
such as talotrexin or trimetrexate (TMQ) are not substrates 
of FPGS and do not require activation by polyglutamation 
for anticancer activity.37
Cellular targets: TYMS, DHFR, GARFT, 
and AiCARFT
Antifolates are inhibitors of key enzymes in folate metabolism, 
namely DHFR, β-glycinamide ribonucleotide   transformylase 
(GARFT), 5′-amino-4′-imidazolecarboxamide ribonucleotide 
transformylase (AICARFT), and thymidylate   synthetase 
(TYMS). GARFT and AIRCARFT are two key enzymes 
of the de novo purine biosynthesis. In a first step, GARFT 
enables the formation of the purine imidazole ring of purines. 
The substrate for this reaction is 10′-formyl-THF, which 
is synthesized from THF and formate, a step mediated by 
10′-formyl-THF synthetase. In a second step, AICARFT 
generates inosine monophosphate, which serves as the pre-
cursor for purine nucleotides adenylate (AMP) and guanylate 
(GMP). DHFR catalyzes the reduction of DHF to 5′,6′,7′,8′-
THF, which is converted to 5′,10′-methyltetrahydrofolate 
(5′,10′-MTHF), the substrate for TYMS.38 TYMS catalyzes 
the initial step in DNA synthesis, in which deoxythymidine 
monophosphate (dTMP), a precursor of DNA synthesis, 
is generated from deoxyuridine monophosphate (dUMP), 
resulting in the oxidation of MTHF to DHF. This metabolic 
step is essential for de novo synthesis of thymidine nucle-
otides for DNA synthesis. DHFR was the first enzyme to be Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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identified as a cellular target for the antifolates aminopterin 
and MTX.39 The latter exhibits its anticancer effect by almost 
irreversible inhibition of DHFR, with subsequent   disruption 
of purine and pyrimidine synthesis.40 Newer antifolates have 
been designed with a higher affinity toward DHFR, eg, 
talotrexin, with a 15-fold increased affinity when compared 
with MTX.37
Mechanisms of resistance
Antifolate resistance might result from impaired   cellular 
influx or increased efflux, impaired polyglutamation, 
increased expression, or mutation of cellular targets, or intra-
cellular accumulation of THF cofactors. Various transport-
resistant phenotypes have been described in MTX-resistant 
cell line models, some of them resulting from mutations of 
the RFC gene,41–43 and others from RFC overexpression.44–46 
A genetic polymorphism within the RFC gene (80G . A) 
results in replacement of arginine in position 27 with 
histidine,47 and is associated with a worse clinical outcome 
in children with acute lymphoblastic leukemia (ALL) 
receiving MTX.48 In osteosarcoma, which is known for its 
intrinsic resistance to conventionally dosed MTX, mutations 
at the 3′-UTR and promoter methylation of the RFC were 
described.49 The role of FR is less well characterized and 
more controversial. Although overexpression of FR-α was 
found to predict resistance to platinum-based chemotherapy 
in ovarian cancer patients,50 suppression of FR expression by 
gene methylation was also found as a potential mechanism of 
resistance.51 Similarly, hypermethylation of the PCFT gene 
(SLC46A1) was found in a resistant HeLa cell line.52 Mul-
tidrug resistance-associated proteins (MRP or ABCC) 1–4 
confer the efflux of MTX and have been shown to potentially 
confer resistance to MTX in cell line models.53,54 However, 
MTX polyglutamates have low affinity toward the ABCC 
transporters, which is why this type of resistance might not 
be clinically relevant. However, breast cancer resistance pro-
tein (BCRP or ABCG2) also transports polyglutamates out 
of the cell, and mutations within the ABCG2 gene (at amino 
acid position 482) have been shown to confer resistance to 
various antifolates.55,56 Overexpression of P-glycoprotein 
(MDR1) is suggested to be important for antifolate resis-
tance in the presence of a defective RFC or in case high 
doses of MTX are administered.57 Impaired polyglutamation 
is another mechanism that is of special importance for the 
classical antifolates that undergo extensive polyglutamation 
to be active. Finally, amplification of the gene encoding for 
DHFR has been identified in ALL,58 ovarian cancer,59 and 
soft-tissue sarcoma60 as a potential mechanism of resistance 
to MTX, but the clinical relevance of such amplifications is 
unclear at present.61
Specific substances
Classical antifolates
The classical antifolates have a similar structure to MTX, 
utilize the RFC for entering human cells, and are subject to 
intracellular polyglutamation.
MTX
MTX is one of the earliest anticancer drugs and is exten-
sively used in lymphoma, acute lymphoblastic leukemia, and 
osteosarcoma. The drug competitively inhibits DHFR and, 
to a lesser extent, GARFT, AICARFT, and TYMS. Although 
thymidylate depletion is the main cytotoxic driver of MTX, 
inhibition of GARFT and AICARFT also results in impaired 
purine synthesis. As a result of their inability to synthesize 
DNA and RNA, the malignant cells are unable to proliferate 
and cause further damage, resulting in cell apoptosis.
Pharmacology
7-Hydroxymethotrexate (7-OH-MTX) is the main metabo-
lite in serum following MTX infusion,62 and it contributes 
to activity and toxicity. The concentrations of 7-OH-MTX 
exceed those of the parent compound in plasma shortly 
after the infusion.63 Both MTX and 7-OH-MTX exhibit 
first-order pharmacokinetics.62 MTX is eliminated by renal 
excretion involving passive glomerular filtration and active 
tubular reabsorption and secretion. 7-OH-MTX is also renally 
cleared but more slowly than MTX. Renal elimination is 
prolonged in patients with renal impairment or third-space 
fluid collections, due to slow redistribution of MTX from 
these extravascular compartments.62 MTX is prone to drug–
drug interactions, especially nonsteroidal antirheumatics 
(NSARs).64 The uptake of MTX into the cell is primarily 
mediated by the RFC and, to a lesser amount, by the FR-α. 
Intracellularly, MTX undergoes extensive γ-polyglutamation 
by FPGS, and these negatively charged polyglutamates are 
retained intracellularly. Polyglutamates can also undergo 
hydrolation by γ-glutamyl hydrolase (GGH, also known as 
folylpolyglutamate hydrolase or FPGH) into short-chain 
polyglutamates.65,66 The MTX pentaglutamate moiety is 
most active, with Ki values 100 times below Ki values of the 
nonglutamated compound.
High-dose MTX
MTX at doses $1 g/m2 is the backbone for treating diseases 
such as primary central nervous system lymphoma (PCNSL), Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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osteosarcoma, or ALL. Careful patient selection, adequate 
hydration and urinary alkalinization, avoidance of drug 
interactions, drainage of third-space fluids, and TDM with 
appropriate adjustment of leucovorin (LV) rescue make 
HDMTX a well-tolerated treatment option most of the time. 
LV rescue starts 24 h after the start of MTX infusion at a 
dose of 15 mg/m2 IV push every 6 h for 3 days and should 
be continued until serum MTX concentrations drop below 
0.05 µmol/L. Despite supporting measures, acute renal 
failure is seen in #2% of patients receiving HDMTX, as a 
consequence of the precipitation of MTX and 7-OH-MTX 
in the kidney tubules.67 Because of considerable interpatient 
variability, TDM is essential to identify patients at high risk 
for severe toxicity, and the need for increased hydration or 
prolonged LV rescue. Before TDM with supplemental LV 
rescue was incorporated into HDMTX regimens, toxicity 
was substantial, including a 6% fatality rate;68 80% of these 
fatalities were attributed to severe myelosuppression, which 
resulted in either sepsis or hemorrhage, and 20% were attrib-
uted to renal failure. Conventional treatment for HDMTX-
induced renal dysfunction includes prompt escalation of 
LV rescue and adequate hydration and urine alkalinization, 
provided adequate urine output can be maintained. MTX 
removal by hemodialysis is of potential value in refractory 
cases. Finally, carboxypeptidase-G2 (CPDG2), a recombi-
nant bacterial enzyme that hydrolyzes MTX to the inactive 
metabolite 2,4-diamino-N10-methylpteroic acid (DAMPA), 
is another option in refractory cases of MTX-associated 
renal dysfunction. CPDG2 lowers plasma concentrations 
of MTX within 15 min of administration by roughly 99%.69 
More recent studies suggest individual exposure to MTX to 
be an important predictor of a favorable treatment response 
in patients with PCNSL,14,15 but this awaits prospective 
validation.
Raltitrexed
Raltitrexed is a selective and direct TYMS inhibitor. As an 
analog of the THF cofactor, it cannot be incorporated into 
DNA, and cellular accumulation of dUMP does not result in 
resistance to raltitrexed.70 Its long-lasting inhibition of TYMS 
allows a convenient 3-weekly schedule of administration. 
Raltitrexed is approved in many countries (except the United 
States) for advanced colorectal cancer, but its utilization is 
mainly limited to patients who are intolerant to 5-fluorouracil 
(5-FU). Although raltitrexed proved to be equally active to 
5-FU/LV in advanced colorectal cancer, there were some 
raltitrexed-associated deaths due to combined gastrointes-
tinal and hematologic toxicity.71 Combining the phase III 
MCRC trials, raltitrexed-related mortality (1.6%–4%) was 
greater than with 5-FU (1.2%–2.8%).72 This occurred in 
spite of a significantly lower all-cause serious toxicity rate 
with raltitrexed and has been attributed to administration 
of raltitrexed after a toxic event or in the presence of renal 
impairment.73 Patient education, monitoring of renal function, 
and supportive measures are essential in the management of 
patients receiving raltitrexed.74
Pharmacology
Raltitrexed predominantly enters the cell by RFC and then 
undergoes polyglutamation, with the polyglutamated form 
again being more potent than the parent compound. With 
repeated administration at 3-weekly intervals, no clinically 
significant accumulation of raltitrexed was found in patients 
with normal renal function.75 Raltitrexed is contraindicated 
in patients with severe renal or hepatic impairment and/or 
clinically significant cardiac arrhythmias requiring drug 
therapy. The importance of dose reductions in patients with 
reduced creatinine clearance is critical in preventing subse-
quent severe toxicity. In patients after accidental overdos-
ing or those suffering from severe toxicity, LV rescue is of 
potential value.
Pralatrexate
Pralatrexate (PDX; 10′-propargyl 10′-deazaaminopterin) is a 
newer antifolate that was rationally designed to have a high 
affinity for the RFC, resulting in increased cellular internal-
ization.76 In a phase II lymphoma study, PDX demonstrated 
some activity against peripheral T-cell lymphoma (TCL).77 
Subsequently, the multicenter confirmatory phase II PROPEL 
(Pralatrexate in Relapsed or Refractory Peripheral T-cell 
Lymphoma) trial has led to the approval of PDX in the United 
States for relapsed or refractory TCL.78,79 Treatment response 
in a total of 109 evaluable patients in the PROPEL trial was 
29%, with 12 patients (11%) achieving a complete response.79 
The median duration of response was 10.1 months. Mucosal 
inflammation was seen in .70% of patients but was usually 
mild to moderate. Hematological toxicity consists of severe 
thrombocytopenia in a third of patients and severe anemia 
in 16% of patients. Febrile neutropenia was noted in 5% of 
cases. Patients should receive supplementation with B12 and 
folic acid to avoid severe toxicity.
PDX was rationally designed to have high affinity for 
the RFC, which leads to better cellular internalization of 
the drug and a greater antitumor effect when compared with 
MTX.80 The structural difference between PDX and MTX is 
based on the presence of a propargyl group substitution at Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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carbon 10 instead of the methyl group in MTX. The basis of 
increased efficacy of PDX in vitro is based on its increased 
affinity for the RFC, but whether this is enough to overcome 
MTX resistance is unknown. PDX effectively binds to and 
inactivates DHFR, depleting intracellular reduced folate 
stores and blocking DNA synthesis.
Lometrexol
Lometrexol (LMTX) is a potent and selective   inhibitor 
of GARFT, with broad antitumor spectrum. GARFT 
catalyzes the formation of purines from the reaction of 10′-
formyltetrahydrofolate (10′-FTHF) to THF. Its inhibition 
results in a depletion of intracellular purine levels. LMTX 
enters the cell via the RFC and undergoes extensive polyglu-
tamation, with a slow elimination of polyglutamates. Without 
folic acid supplementation, severe cumulative myelosup-
pression and mucositis are likely.81 At present, LMTX is not 
approved as an anticancer agent.
edatrexate
Edatrexate (EDX) is a classic antifolate with a more efficient 
intracellular polyglutamation compared with MTX.82 EDX 
polyglutamates are potent inhibitors of DHFR but less potent 
inhibitors of TYMS.83 EDX exhibits saturable, nonlinear 
Michaelis–Menten pharmacokinetics, with #55% of EDX 
undergoing renal excretion as unchanged parent compound.84 
As EDX was associated with severe stomatitis, toxic der-
matitis, and even fatalities,85 clinical development was   
halted.
Nonpolyglutamable classical 
antifolates
Talotrexin
Talotrexin (PT-523) is a newer antifolate and potent antago-
nist of DHFR. Talotrexin combines characteristics of both 
the classical and nonclassical antifolates. As talotrexin does 
not contain a glutamic acid side chain, it is not converted 
to intracellular polyglutamates, with a potential advantage 
for drug safety and less bone marrow toxicity.86 The drug 
binds tightly to DHFR, with an inhibitory constant (Ki) of 
0.35 pmol/L, 15-fold lower than for MTX. Talotrexin exhib-
its linear pharmacokinetics with a rapid initial disposition 
phase.87 Patients with relapsed or refractory leukemia or MDS 
received talotrexin for five subsequent days, together with 
supplemental folic acid and vitamin B12.87 Dose-limiting tox-
icity was stomatitis, and talotrexin 0.6 mg/m2/day for 5 days 
every 3 weeks was recommended for phase II studies, where 
evaluation in patients with refractory ALL is ongoing.87
Nonclassical antifolates
Nonclassical antifolates do not contain glutamic acid and are 
not polyglutamable; they are more lipophilic than the classi-
cal antifolates and enter cells by passive diffusion.
TMQ
TMQ is a nonclassical, lipophilic quinazoline derivative 
with a high inhibitory potency toward DHFR.88 Because 
of its lipophilicity, TMQ can rapidly enter cells by a non-
energy-dependent process. Unlike most antifolate drugs, 
TMQ is mainly eliminated by hepatic metabolism instead 
of renal excretion, with a terminal elimination half-life of 
15–20 h.88 Cell lines resistant to MTX because of deficiencies 
in folate transport generally retain their sensitivity to TMQ. 
As TMQ lacks the glutamic acid side chain, it cannot be poly-
glutamated and is not retained within the cell for prolonged 
periods of time.89 Although TMQ has undergone broad phase 
II testing in solid tumors,90 results were disappointing and 
there is no current indication in oncology.
Piritrexim
Piritrexim (PTX) is an oral lipophilic antifolate that is not a 
substrate of the active folate transport systems but enters cells 
via an energy-independent process and is effective against 
cancer cells resistant to MTX because of transport defects.91 
PTX is not polyglutamated by FPGS, but it is a potent inhibitor 
of DHFR and TYMS. Oral absorption of PTX is rapid, with 
an overall bioavailability of 75%–95%.92 The terminal half-
life following oral administration is 4.5–5.6 h,92 with hepatic 
metabolism being the primary route of drug clearance. Despite 
the potential as an oral antifolate, PTX did not show any 
therapeutic advantage over more established antifolates.
Nolatrexed
Nolatrexed (Thymitaq, TM) is a nonclassical, lipophilic anti-
folate and a noncompetitive, high-affinity TYMS inhibitor. 
TM causes extensive dTMP depletion and dUMP accumula-
tion, causing thymineless cell death. TM is not dependent on 
the cell cycle, as high concentrations of TM failed to induce 
S-phase arrest but still resulted in apoptosis.93 Although TM 
itself is lipophilic, it can be administered via intravenous 
infusion as a water-soluble dihydrochloride salt. Due to its 
lipophilicity, TM enters cells by passive diffusion and does 
not undergo polyglutamation.94 TM was granted orphan 
drug status for the treatment of unresectable hepatocel-
lular   carcinoma by the US Food and Drug Administration 
(2001) and the European Medicines Agency (2007), based 
on a randomized phase III Asian study comparing TM with Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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doxorubicin, and two North American phase II studies.95 TM 
has never gained widespread use in oncology.
MTA
Pemetrexed
Pemetrexed has been approved in combination with cisplatin 
as a first-line treatment for advanced non-squamous-cell 
lung cancer,10 as a single agent for relapsed NSCLC after 
platinum-containing chemotherapy,96 and in combination 
with cisplatin for the treatment of pleural mesothelioma.9 
Important is histotype-selective activity of pemetrexed, with 
a significant benefit seen only in patients with non-squamous-
cell lung cancer,10 potentially as a consequence of increased 
TYMS expression in tumors of squamous histology.97 Sup-
portive treatment with oral folic acid 0.5 mg/day and intra-
muscular vitamin B12 1 mg every 9 weeks is routinely used, 
as it has been shown to reduce the incidence of potentially 
fatal myelosuppression.98 Pemetrexed is a cell-cycle-depen-
dent antifolate with a 6–5-fused pyrrolopyrimidine-based 
nucleus,99 and it inhibits TYMS, DHFR, GARFT, AICARFT, 
and C1-THF synthase, which catalyzes the incorporation of 
a formyl group into 10′-FTHF for purine synthesis, and the 
incorporation of a methylene group into 5′,10′-MTHF for 
thymidylate synthesis. Mechanisms of resistance include 
diminished accumulation of pemetrexed polyglutamates due 
to decreased activity of FPGS,100 increased enzymatic cleav-
age of pemetrexed poly-γ-glutamates by high intracellular 
GH activity, and TYMS amplification.101 Inhibition of TYMS 
leads to intracellular accumulation of dUMP and subsequent 
efflux of deoxyuridine (dUrd) into the circulation, which can 
be used as a pharmacodynamic marker of in vivo TYMS 
inhibition following administration of pemetrexed.102
Pharmacology
Pemetrexed is transported into cells mainly by the RFC and 
undergoes rapid intracellular transformation by FPGS to 
the more potent polyglutamate derivatives.103 Pemetrexed 
has a small steady-state volume of distribution of about 
15 L and is rapidly eliminated from plasma with a termi-
nal elimination half-life of between 2 and 5 h at doses of 
525–700 mg/m2. Pemetrexed undergoes mainly urinary 
excretion as an unchanged parent compound. Furthermore, 
pemetrexed exhibits dose-proportional increases in plasma 
concentration and no signs of accumulation in patients with 
normal renal function. Third-space accumulation seems not 
to play a clinically significant role.104 As pemetrexed is often 
combined with potentially nephrotoxic cisplatin, adequate 
monitoring of renal function is important. Recommendations 
for the management of pemetrexed toxicity in the presence 
of renal failure have not been established, but treatment 
options with LV, folate, thymidine, carboxypeptidase, or 
hemodialysis are all possible.105 Homocysteine is a marker 
for overall folate status in the body and predicted severe 
pemetrexed-associated toxicity in a clinical study.106
Summary
The approval of pemetrexed for the first-line treatment of 
non-squamous-cell lung cancer, second-line treatment of 
NSCLC, and first-line treatment of malignant pleural meso-
thelioma has substantially added to the clinical importance 
of antifolates in oncology. Treatment individualization ever 
since has played an important role in the development of 
antifolate drugs. Although LV rescue and TDM are standard 
for HDMTX regimens, and folate and B12 supplementation is 
standard for pemetrexed to increase MTD, new strategies will 
include pharmacogenetic markers such as tumoral TYMS 
expression for further improvement of antifolate treatment.
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